| Cash Flow | 2025-09-30 |
|---|---|
| Net loss | -77,111 |
| Depreciation and amortization | 1,437 |
| Loss on note | -1,159 |
| Loss on extinguishment of debt | -2,092 |
| Bad debt | 31 |
| Issuance costs of derivative instruments | 1,837 |
| Inventory write-off | 1,318 |
| Amortization of debt discount | 65 |
| Stock-based compensation | 4,228 |
| Accounts receivable | -170 |
| Inventory | -1,362 |
| Prepaid expenses and other | 2,159 |
| Accounts payable | 3,732 |
| Lease liabilities and rou asset, net | -18 |
| Accrued expenses and other current liabilities | 1,663 |
| Net cash used in operating activities | -60,194 |
| Issuance of note | 2,012 |
| Purchase of property and equipment | 1,495 |
| Net cash used in investing activities | -3,507 |
| Repurchase of common stock | 5,949 |
| Payment of term loan | 9,650 |
| Proceeds, net of 5,750 and 3,942 expenses, from sale of common stock and warrants | 170,986 |
| Net cash provided by financing activities | 155,387 |
| Effect of currency rate change on cash | -17 |
| Net increase in cash, cash equivalents and restricted cash | 91,669 |
| Cash and cash equivalents at beginning of period | 99,680 |
| Cash and cash equivalents at end of period | 191,349 |
Tonix Pharmaceuticals Holding Corp. (TNXP)
Tonix Pharmaceuticals Holding Corp. (TNXP)